Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Pharmaceutical company Syri fined for manufacturing defective medicine

London-based pharmaceutical manufacturer, Syri Ltd, has been fined £51,000 and ordered to pay costs of £104,898 by Aylesbury Crown Court, after being convicted of supplying a medicinal product which failed to meet the quality specified in a prescription.

The decision follows an investigation by the Medicines and Healthcare products Regularly Agency (MHRA) and a prosecution brought by the Crown Prosecution Service (CPS).


The investigation was prompted by a child suffering multiple seizures, which eventually led to the hospitalisation. The child was prescribed magnesium glycerophosphate to prevent seizures, but the medicine manufactured by the company contained just 12 per cent of the strength specified in the prescription.

The MHRA was informed about the issue through a report from Milton Keynes University Hospital.

After an inspection, the regulator found that the manufacturing method and the checks to ensure appropriate standards were not met for the medicine, jeopardizing the health of the child.

Dr Alison Cave, MHRA chief safety officer, said: “Pharmaceutical companies such as Syri Ltd have a legal obligation to ensure they produce and supply medicines that work and are manufactured to the required standards.  The patient has recovered, but the consequences could have been much more serious if it hadn’t been for the swift action of hospital staff.

“Patient safety is our top priority. The Agency will not hesitate to take robust enforcement action when serious failings that put patients at risk are identified.”

Laura Walters, special crown prosecutor of the Crown Prosecution Service said: “Syri Limited, as with all pharmaceutical providers, have a vital responsibility to produce medicines accurately and safely, in the form specified in a prescription. Fortunately, the mistake they made was not fatal in this case. This was not an isolated mistake although our prosecution was only concerned with this one serious incident.

“These types of prosecutions are thankfully rare, but this conviction and sentence should serve as a reminder for all pharmaceutical companies of the need for absolute care in providing essential medications to the public.”

More For You

A woman using a period tracker app

Cambridge University academics have flagged concerns over the safety of period tracker apps

Pic credit: iStock

Users of period tracking apps face privacy, safety risk, say experts

The report said the apps provide a "gold mine" of data for consumer profiling and warn that in the wrong hands it could pose a safety risk

CAMBRIDGE UNIVERSITY academics have flagged concerns over the safety of period tracker apps and warned that the women using them could face privacy and safety risks.

Keep ReadingShow less
Patients to get test results via NHS app

An investment of £50m has been made to upgrade the NHS app

Patients to get test results via NHS app

Millions of patients will now be able to access test results and get appointment reminders on their smartphones as the government tries to position the NHS app as the default mode of communication and steer away from traditional methods like letters.

An investment of £50m has been made to upgrade the NHS app and the health service hopes to save £200m over the next three years.

Keep ReadingShow less
Health minister assures House of Lords on measures to tackle UK-wide Creon drug shortage

Baroness Merron

Government taking steps to mitigate shortage of cancer drug Creon

Baroness Merron on Monday (9) assured the House of Lords that the government is taking measures to mitigate the shortage of pancreatic cancer drug Creon across the country.

Raising the issue, Baroness Margaret Ritchie wanted to know about the steps being taken by the government to ease the misery of patients suffering from pancreatic cancer.

Keep ReadingShow less
Janet Morrison: "Eventual outcome of spending review needs to tackle pharmacy underfunding"

Janet Morrison

Janet Morrison: "Eventual outcome of spending review needs to tackle pharmacy underfunding"

Community Pharmacy England (CPE) chief executive Janet Morrison has welcomed chancellor Rachel Reeves announcement today that day-to-day spending on the NHS will increase by £29bn a year but insisted that it must reflect in securing the future of pharmacy.

Reeves also revealed that the government will be increasing the NHS technology budget by almost 50 per cent, with £10bn of investment to "bring our analogue health system into the digital age, including through the NHS app".

Keep ReadingShow less
Lynsey Cleland named GPhC chief standards officer

Lynsey Cleland

Pic credit: X

Lynsey Cleland named GPhC chief standards officer

The General Pharmaceutical Council (GPhC) has brought back Lynsey Cleland to lead on a number of important departments in the role of chief standards officer.

Cleland had previously held a number of senior positions at GPhC, including director of Scotland.

Keep ReadingShow less